The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak

dc.citation.titleInternational Braz J Uroles
dc.creatorLauxmann, Martin Alexander
dc.creatorSantucci, Natalia Estefanía
dc.creatorAutrán-Gómez, Ana María
dc.date.accessioned2020-08-04T15:35:35Z
dc.date.available2020-08-04T15:35:35Z
dc.date.issued2020-07-27
dc.descriptionThe SARS-CoV-2, a newly identified β-coronavirus, is the causative agent of the third large-scale pandemic from the last two decades. The outbreak started in December 2019 in Wuhan City, Hubei province in China. The patients presented clinical symptoms of dry cough, fever, dyspnea, and bilateral lung infiltrates on imaging. By February 2020, The World Health Organization (WHO) named the disease as Coronavirus Disease 2019 (COVID-19). The Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV) recognized and designated this virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 uses the same host receptor, angiotensin-converting enzyme 2 (ACE2), used by SARS-CoV to infect humans. One hypothesis of SARSCoV-2 origin indicates that it is likely that bats serve as reservoir hosts for SARSCoV-2, being the intermediate host not yet determined. The predominant route of transmission of SARS-CoV-2 is from human to human. As of May 10th 2020, the number of worldwide confirmed COVID-19 cases is over 4 million, while the number of global deaths is around 279.000 people. The United States of America (USA) has the highest number of COVID-19 cases with over 1.3 million cases followed by Spain, Italy, United Kingdom, Russia, France and Germany with over 223.000, 218.000, 215.000, 209.000, 176.000, and 171.000 cases, respectively.es
dc.description.filFil: Autrán-Gómez, Ana María. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clínica y Experimental de Rosario, CONICET-UNR; Argentinaes
dc.formatapplication/pdf
dc.format.extent6-18es
dc.identifier.issn1677-6119es
dc.identifier.urihttp://hdl.handle.net/2133/18559
dc.language.isoenges
dc.publisherSociedade Brasileira de Urologiaes
dc.relation.publisherversionhttps://doi.org/10.1590/s1677-5538.ibju.2020.s101es
dc.rightsopenAccesses
dc.rights.holderAutoreses
dc.rights.texthttps://creativecommons.org/licenses/by/4.0/deed.en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.es
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.en*
dc.subjectCoronaviruses
dc.subjectSpike proteines
dc.subjectSARS-CoV-2es
dc.subjectDiagnosises
dc.titleThe SARS-CoV-2 Coronavirus and the COVID-19 Outbreakes
dc.typearticle
dc.typeartículo
dc.typepublishedVersion
dc.type.collectionarticulo
dc.type.versionpublishedVersiones

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1677-6119-ibju-46-s01-0006.pdf
Tamaño:
400.7 KB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.59 KB
Formato:
Item-specific license agreed upon to submission
Descripción: